Quantitative evaluation of ABC transporter-mediated drug resistance based on the determination of the anticancer activity of camptothecin against breast cancer stem cells using TIRF

2016 ◽  
Vol 8 (6) ◽  
pp. 704-711 ◽  
Author(s):  
Parthasarathy Arumugam ◽  
Joon Myong Song
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Drug Resistance ◽  
Cancer Stem Cells ◽  
Total Internal Reflection ◽  
Breast Cancer Stem Cells ◽  
Simultaneous Evaluation ◽  
Drug Resistance Profile ◽  
Drug Efflux Pumps

Total internal reflection fluorescence microscopy (TIRF) and Qdot probe based analytical method for the simultaneous evaluation of the cytotoxic ability of camptothecin and the drug resistance profile upon the inhibition of drug efflux pumps in breast cancer stem cells.

Spectral overlap-free quantum dot-based determination of benzo[a]pyrene-induced cancer stem cells by concurrent monitoring of CD44, CD24 and aldehyde dehydrogenase 1

2015 ◽  
Vol 51 (11) ◽  
pp. 2118-2121 ◽  
Author(s):  
Yumi Shim ◽  
Joon Myong Song
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Quantum Dot ◽  
Aldehyde Dehydrogenase ◽  
Breast Cancer Stem Cells ◽  
Induced Mutation ◽  
Aldehyde Dehydrogenase 1 ◽  
Mcf 7

In this study, it was found that breast cancer stem cells (CSCs) are formed from MCF-7 cells by benzo[a]pyrene (BP)-induced mutation.

scholarly journals The Breast Cancer Stem Cells Traits and Drug Resistance

2021 ◽  
Vol 11 ◽  
Author(s):  
Qinghui Zheng ◽  
Mengdi Zhang ◽  
Fangfang Zhou ◽  
Long Zhang ◽  
Xuli Meng
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Drug Resistance ◽  
Cancer Stem Cells ◽  
Drug Efficacy ◽  
Resistance Mechanisms ◽  
Therapeutic Strategies ◽  
Breast Cancer Stem Cells ◽  
Drug Resistant ◽  
Related Drug

Drug resistance is a major challenge in breast cancer (BC) treatment at present. Accumulating studies indicate that breast cancer stem cells (BCSCs) are responsible for the BC drugs resistance, causing relapse and metastasis in BC patients. Thus, BCSCs elimination could reverse drug resistance and improve drug efficacy to benefit BC patients. Consequently, mastering the knowledge on the proliferation, resistance mechanisms, and separation of BCSCs in BC therapy is extremely helpful for BCSCs-targeted therapeutic strategies. Herein, we summarize the principal BCSCs surface markers and signaling pathways, and list the BCSCs-related drug resistance mechanisms in chemotherapy (CT), endocrine therapy (ET), and targeted therapy (TT), and display therapeutic strategies for targeting BCSCs to reverse drug resistance in BC. Even more importantly, more attention should be paid to studies on BCSC-targeted strategies to overcome the drug resistant dilemma of clinical therapies in the future.

scholarly journals Ethnicity influences breast cancer stem cells' drug resistance

2018 ◽  
Vol 24 (4) ◽  
pp. 701-703 ◽  
Author(s):  
Mohamed Kamal ◽  
Ebtesam H.O. Nafie ◽  
Shimaa Elsers ◽  
Salma Alanwar ◽  
Rawayeh Ibrahim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Drug Resistance ◽  
Cancer Stem Cells ◽  
Breast Cancer Stem Cells

scholarly journals Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue

2021 ◽  
Vol 22 (9) ◽  
pp. 4673
Author(s):  
Vrinda Gote ◽  
Anantha Ram Nookala ◽  
Pradeep Kumar Bolla ◽  
Dhananjay Pal
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Drug Resistance ◽  
Metastatic Breast Cancer ◽  
Cancer Stem Cells ◽  
Metastatic Breast ◽  
Future Perspective ◽  
Cancer Drug ◽  
Breast Cancer Stem Cells ◽  
Mesenchymal Transition

Breast cancer, specifically metastatic breast, is a leading cause of morbidity and mortality in women. This is mainly due to relapse and reoccurrence of tumor. The primary reason for cancer relapse is the development of multidrug resistance (MDR) hampering the treatment and prognosis. MDR can occur due to a multitude of molecular events, including increased expression of efflux transporters such as P-gp, BCRP, or MRP1; epithelial to mesenchymal transition; and resistance development in breast cancer stem cells. Excessive dose dumping in chemotherapy can cause intrinsic anti-cancer MDR to appear prior to chemotherapy and after the treatment. Hence, novel targeted nanomedicines encapsulating chemotherapeutics and gene therapy products may assist to overcome cancer drug resistance. Targeted nanomedicines offer innovative strategies to overcome the limitations of conventional chemotherapy while permitting enhanced selectivity to cancer cells. Targeted nanotheranostics permit targeted drug release, precise breast cancer diagnosis, and importantly, the ability to overcome MDR. The article discusses various nanomedicines designed to selectively target breast cancer, triple negative breast cancer, and breast cancer stem cells. In addition, the review discusses recent approaches, including combination nanoparticles (NPs), theranostic NPs, and stimuli sensitive or “smart” NPs. Recent innovations in microRNA NPs and personalized medicine NPs are also discussed. Future perspective research for complex targeted and multi-stage responsive nanomedicines for metastatic breast cancer is discussed.

Sign in / Sign up

Export Citation Format

Share Document